Idenix Pharmaceuticals Announces Nucleotide Prodrug Program Poster Presentation At The American Association For The Study Of Liver Diseases (AASLD) Annual Meeting

CAMBRIDGE, Mass., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced a poster presentation featuring preclinical data for its uridine nucleotide prodrug candidate for the treatment of hepatitis C virus (HCV) infection at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place in Washington, DC, November 1-5, 2013. Full abstracts can now be viewed at the AASLD website at www.aasld.org .

The following abstract will be presented in a poster session during the AASLD Annual Meeting in the Poster Hall on Saturday, November 2, 2013, 2:00pm – 7:30pm Eastern Time:
  • Abstract No. 485: "A Novel Uridine Nucleotide Prodrug, IDX20963, and Its Potential for Use in a Low-Dose Direct-Acting Antiviral Regimen for HCV."

ABOUT HEPATITIS C

Hepatitis C virus is a common blood-borne pathogen infecting three to four million people worldwide annually. The World Health Organization (WHO) estimates that more than 170 million people worldwide are chronically infected with HCV, representing a nearly 5-fold greater prevalence than human immunodeficiency virus.

ABOUT IDENIX

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases.  Idenix's current focus is on the treatment of patients with hepatitis C infection.  For further information about Idenix, please refer to www.idenix.com .
CONTACT: Idenix Pharmaceuticals Contact:         Teri Dahlman, (617) 995-9807

Idenix Pharmaceuticals logo

If you liked this article you might like

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015

Health Care Stocks: A Year in Review and Predictions for 2015

Health Care Stocks: A Year in Review and Predictions for 2015

'Fast Money' Recap: Next Stop, S&P 2,100?

'Fast Money' Recap: Next Stop, S&P 2,100?

Cramer: Every Which Way But Short

Cramer: Every Which Way But Short

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout

Sarissa Capital: Good Start With Idenix Pharmaceuticals Buyout